AR071146A1 - Inhibicion relacionada con arni de la via de senales tnf alfa para el tratamiento de angiogenesis ocular, uso de una molecula de arn de interferencia y molecula de arn de interferencia - Google Patents
Inhibicion relacionada con arni de la via de senales tnf alfa para el tratamiento de angiogenesis ocular, uso de una molecula de arn de interferencia y molecula de arn de interferenciaInfo
- Publication number
- AR071146A1 AR071146A1 ARP080103367A AR071146A1 AR 071146 A1 AR071146 A1 AR 071146A1 AR P080103367 A ARP080103367 A AR P080103367A AR 071146 A1 AR071146 A1 AR 071146A1
- Authority
- AR
- Argentina
- Prior art keywords
- molecula
- interference rna
- arni
- treatment
- tnfalfa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
ARN de interferencia para la inhibicion de factor de necrosis tumoral alfa (TNFalfa) al silenciar la expresion de mARN del receptor 1 de receptor de superficie celular TNFalfa (TNFR1), o al silenciar la expresion de mARN de la enzima convertidora de TNFalfa (TACE/ADAM17). El silenciamiento de dichos objetivos de TNFalfa, en particular, es util para tratar pacientes que tienen una condicion relacionada con TNFalfa o están en situacion de riesgo de desarrollar una condicion relacionada con TNFalfa, tales como angiogénesis ocular, edema de retina, isquemia de retina y retinopatía diabética.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95382507P | 2007-08-03 | 2007-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071146A1 true AR071146A1 (es) | 2010-06-02 |
Family
ID=40263006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103367 AR071146A1 (es) | 2007-08-03 | 2008-08-01 | Inhibicion relacionada con arni de la via de senales tnf alfa para el tratamiento de angiogenesis ocular, uso de una molecula de arn de interferencia y molecula de arn de interferencia |
Country Status (6)
Country | Link |
---|---|
US (8) | US20090036396A1 (es) |
AR (1) | AR071146A1 (es) |
CL (1) | CL2008002277A1 (es) |
TW (1) | TW200916117A (es) |
UY (1) | UY31267A1 (es) |
WO (2) | WO2009020847A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200808360A (en) | 2006-04-13 | 2008-02-16 | Alcon Mfg Ltd | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
AR071146A1 (es) | 2007-08-03 | 2010-06-02 | Alcon Res Ltd | Inhibicion relacionada con arni de la via de senales tnf alfa para el tratamiento de angiogenesis ocular, uso de una molecula de arn de interferencia y molecula de arn de interferencia |
CN106943647B (zh) | 2010-08-05 | 2020-09-04 | B·布朗·梅尔松根有限公司 | 针安全装置和组件 |
WO2014174834A1 (ja) * | 2013-04-25 | 2014-10-30 | 国立大学法人山口大学 | 神経疾患治療剤 |
CN107904239B (zh) * | 2014-12-25 | 2020-11-27 | 广州市锐博生物科技有限公司 | 抑制ADAMTS-5基因的siRNA及其应用 |
CN104498498A (zh) * | 2014-12-25 | 2015-04-08 | 广州市锐博生物科技有限公司 | 抑制ADAM17基因的siRNA及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1267903A4 (en) * | 2000-02-08 | 2003-08-06 | Pharmacia Corp | METHODS OF TREATING GLAUCOMA |
US6531128B1 (en) * | 2000-02-08 | 2003-03-11 | Pharmacia Corporation | Methods for treating glaucoma |
US20050227935A1 (en) * | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
EP1478730A4 (en) * | 2002-02-20 | 2006-01-25 | Sirna Therapeutics Inc | INTERFERENCE RNA-INDUCED INHIBITION OF THE GENE EXPRESSION OF SUPERFAMILY TFN AND TFN RECEPTOR SUPERFAMILY USING SHORT INTERFERENCE NUCLEIC ACID (SINA) |
JP3882725B2 (ja) * | 2002-03-12 | 2007-02-21 | 株式会社デンソー | 車両用回転電機 |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US20090247604A1 (en) * | 2004-02-05 | 2009-10-01 | Intradigm Corporation | RNAi Therapeutics for Treatment of Eye Neovascularization Diseases |
US8084599B2 (en) * | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
KR20070085113A (ko) * | 2004-05-11 | 2007-08-27 | 가부시키가이샤 알파젠 | Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법 |
WO2007016597A2 (en) * | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
KR20120093306A (ko) * | 2006-05-19 | 2012-08-22 | 알콘 리서치, 리미티드 | 종양 괴사 인자 α-관련 증상의 RNAi-매개 억제 |
AR071146A1 (es) | 2007-08-03 | 2010-06-02 | Alcon Res Ltd | Inhibicion relacionada con arni de la via de senales tnf alfa para el tratamiento de angiogenesis ocular, uso de una molecula de arn de interferencia y molecula de arn de interferencia |
-
2008
- 2008-08-01 AR ARP080103367 patent/AR071146A1/es unknown
- 2008-08-01 CL CL2008002277A patent/CL2008002277A1/es unknown
- 2008-08-01 US US12/184,351 patent/US20090036396A1/en not_active Abandoned
- 2008-08-01 UY UY31267A patent/UY31267A1/es not_active Application Discontinuation
- 2008-08-01 TW TW97129263A patent/TW200916117A/zh unknown
- 2008-08-01 WO PCT/US2008/071885 patent/WO2009020847A2/en active Application Filing
- 2008-08-04 US US12/185,182 patent/US20090036397A1/en not_active Abandoned
- 2008-08-04 WO PCT/US2008/072061 patent/WO2009020894A2/en active Application Filing
-
2010
- 2010-06-29 US US12/825,552 patent/US20100267811A1/en not_active Abandoned
-
2011
- 2011-02-21 US US13/031,358 patent/US20110190376A1/en not_active Abandoned
- 2011-06-27 US US13/169,549 patent/US8754202B2/en active Active
-
2014
- 2014-05-05 US US14/270,197 patent/US9139834B2/en active Active
-
2015
- 2015-08-17 US US14/827,418 patent/US9422556B2/en active Active
-
2016
- 2016-07-25 US US15/218,180 patent/US20160326533A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2009020847A3 (en) | 2009-07-23 |
US20160326533A1 (en) | 2016-11-10 |
US20090036396A1 (en) | 2009-02-05 |
US20100267811A1 (en) | 2010-10-21 |
TW200916117A (en) | 2009-04-16 |
CL2008002277A1 (es) | 2009-07-17 |
US8754202B2 (en) | 2014-06-17 |
WO2009020847A2 (en) | 2009-02-12 |
US20090036397A1 (en) | 2009-02-05 |
US9139834B2 (en) | 2015-09-22 |
WO2009020894A3 (en) | 2009-08-27 |
US20110257248A1 (en) | 2011-10-20 |
US20110190376A1 (en) | 2011-08-04 |
US20150344886A1 (en) | 2015-12-03 |
US20140357696A1 (en) | 2014-12-04 |
US9422556B2 (en) | 2016-08-23 |
WO2009020894A2 (en) | 2009-02-12 |
UY31267A1 (es) | 2009-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071146A1 (es) | Inhibicion relacionada con arni de la via de senales tnf alfa para el tratamiento de angiogenesis ocular, uso de una molecula de arn de interferencia y molecula de arn de interferencia | |
AR056852A1 (es) | INHIBICIoN DE HIF1A INTERMEDIADO POR RNAI PARA EL TRATAMIENTO DE ANGIOGENESIS OCULAR | |
DOP2020000241A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
CL2008002351A1 (es) | Compuestos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer. | |
UY30361A1 (es) | Inhibición mediada por el arni de las afecciones vinculadas al factor a (alfa) de necrosis tumoral | |
CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
AR078346A1 (es) | Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
EA200700886A1 (ru) | Соединение тиадиазола и его применение | |
AR067786A1 (es) | Inhibicion relacionada con arni (arn de interferencia) de senales tnfalfa (factor de necrosis tumoral) para el tratamiento de glaucoma | |
CY1115547T1 (el) | Ενωση αζολοκαρβοξαμιδιου ή αλας αυτης | |
GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
CR20120040A (es) | Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades | |
AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
UY33481A (es) | Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular | |
NO20074943L (no) | Roflumilast for behandlingen av diabetes mellitus | |
DOP2011000285A (es) | 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso | |
CR20120086A (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana | |
BRPI0710085B8 (pt) | composições oftálmicas e seus kits | |
NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
PA8784101A1 (es) | Oxazolidinonas sustituidas y su uso | |
CR20120415A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
GT200900319A (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea | |
NO20091630L (no) | CCR2-antagonister for behandling av fibrose | |
BR112014031788A2 (pt) | composições e métodos para o tratamento de diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |